Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18500324 | 1.00 | ABCB1 (0.38) | ABCB1ACHECA1CA2PRKCA | |
| SCHEMBL17211437 | 0.92 | ABCB1 (0.39) | ABCB1PRKCAPRKCDALDH1A1PLAU | |
| SCHEMBL17211435 | 0.92 | ABCB1 (0.39) | ABCB1PRKCAPRKCDALDH1A1PLAU | |
| SCHEMBL15697199 | 0.92 | ABCB1 (0.39) | ABCB1PRKCAPRKCDALDH1A1PLAU | |
| SCHEMBL15675113 | 0.88 | ALDH1A1 (0.38) | ACHEALDH1A1HSD17B10CNR2TDP1 | |
| SCHEMBL17211436 | 0.85 | ABCB1 (0.41) | ABCB1ALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL15697201 | 0.85 | ABCB1 (0.41) | ABCB1ALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL15674715 | 0.85 | ABCB1 (0.41) | ABCB1ALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL17212850 | 0.81 | ABCB1 (0.38) | ABCB1ACHECA1CA2PRKCA | |
| SCHEMBL17212858 | 0.81 | ABCB1 (0.38) | ABCB1ACHECA1CA2PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9566312-B2 | Cyclic peptides and use as medicines | NOVARTIS AG (CH) | 2017-02-14 | — | — | US | disclosed |
| US-20150306172-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | NOVARTIS AG (CH) | 2015-10-29 | — | — | US | disclosed |
| US-9072696-B2 | Cyclic peptides and use as medicines | NOVARTIS AG (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20140134132-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | NOVARTIS AG (CH) | 2014-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134132-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | PPIF, VIP, FKBP1B | ABCB1 724/4885ACHE 4047/4885CA1 1618/4885 |
| US-20150306172-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | PPIF, VIP, MAVS | ABCB1 910/4885ACHE 3911/4885CA1 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.